Algernon Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel, small-molecule therapeutics. The company’s primary strategy centers on repurposing known compounds with established safety profiles to address unmet medical needs, particularly in the realms of pulmonary fibrosis, acute lung injury and central nervous system (CNS) disorders. By leveraging existing pharmacology data, Algernon aims to accelerate its development timelines while managing costs and risks typically associated with early-stage drug discovery.
The lead asset in Algernon’s pipeline is NP-120 (ifenprodil), an orally available small molecule being investigated for idiopathic pulmonary fibrosis (IPF). Following promising preclinical results, the company launched a Phase II clinical trial in Canada to evaluate safety and efficacy in IPF patients. In parallel, Algernon is advancing NP-188, a proprietary formulation of dimethyltryptamine (DMT), through preclinical studies for potential use in acute lung injury models. Additional research efforts include the exploration of NP-353, a CNS-focused program targeting mood and neurodegenerative disorders.
Algernon Pharmaceuticals conducts its research and development activities primarily in Vancouver, British Columbia, with strategic partnerships in Australia to support certain clinical trials. This geographic footprint allows the company to access a diverse patient population and leverage regulatory pathways in both North America and Oceania. Collaboration with academic institutions and contract research organizations underpins Algernon’s translational science approach, aiming to bridge laboratory discoveries with clinical applications efficiently.
Headquartered in Vancouver, Algernon is led by a management team with extensive experience in pharmaceutical development and commercialization. Christopher J. Moreau, Ph.D., serves as Chief Executive Officer, overseeing clinical programs and strategic initiatives. Under his leadership, the company has built a focused pipeline of mid-stage assets and has secured intellectual property protection for its repurposed compounds. As a publicly traded entity on the OTC Markets under the symbol AGNPF, Algernon continues to pursue regulatory approvals and partnerships to advance its therapy candidates toward market entry.
AI Generated. May Contain Errors.
Free AGNPF Stock Alerts